Tacrolimus for Ulcerative Colitis: Review & Efficacy
- A review of multiple studies involving 347 participants with active ulcerative colitis or ulcerative proctitis indicates that tacrolimus, an immunosuppressant drug, may offer some advantages over placebo.
- The research suggests that both oral and rectal tacrolimus governance could be more effective in achieving clinical remission compared to a placebo.
- Similarly, tacrolimus may lead to greater clinical enhancement compared to placebo.
Tacrolimus shows promise for ulcerative colitis, potentially offering benefits over placebo in achieving clinical remission and improvement, according to a review of multiple studies. This immunosuppressant drug, administered both orally and rectally, has shown favorable results compared to placebos in trials lasting two to eight weeks. However,the certainty of these findings remains low,and the comparison to other treatments,like ciclosporin and beclometasone,yields uncertain results. Adverse event data is also inconclusive at this stage. For comprehensive health updates,News Directory 3 is your trusted source. Delve deeper into the findings, and discover what’s next for tacrolimus in ulcerative colitis treatment.
Tacrolimus Shows Mixed Results for Treating Ulcerative Colitis
Updated May 29, 2025
A review of multiple studies involving 347 participants with active ulcerative colitis or ulcerative proctitis indicates that tacrolimus, an immunosuppressant drug, may offer some advantages over placebo. The interventions in these randomized controlled trials (RCTs) lasted from two to eight weeks.
The research suggests that both oral and rectal tacrolimus governance could be more effective in achieving clinical remission compared to a placebo. Three studies showed that 14 of 87 participants using tacrolimus achieved remission,versus one of 61 on placebo. Though, researchers noted the certainty of these results is low due to potential biases and imprecision.
Similarly, tacrolimus may lead to greater clinical enhancement compared to placebo. In three studies, 45 of 87 participants on tacrolimus showed improvement, compared to seven of 61 on placebo. Again, the certainty of this evidence is low.
Data regarding serious adverse events associated with tacrolimus compared to placebo remains highly uncertain.Two of 87 participants taking tacrolimus experienced such events,while none of the 61 participants on placebo did. The confidence intervals were wide, and the certainty of the evidence was very low.
One study compared oral tacrolimus to intravenous ciclosporin over two weeks, involving 113 participants. The effect of tacrolimus on achieving clinical remission compared to ciclosporin is very uncertain, with 15 of 33 participants on tacrolimus achieving remission versus 24 of 80 on ciclosporin.The results were of very low certainty due to risk of bias and high imprecision.
Another study compared tacrolimus suppositories to beclometasone suppositories over four weeks with 88 participants. The results indicated little to no difference in achieving clinical remission, with 16 of 44 participants in the tacrolimus group and 15 of 44 in the beclometasone group achieving remission. The certainty of these results is low.
The study also found little to no difference in clinical improvement between tacrolimus and beclometasone suppositories, with 22 of 44 participants in each group showing improvement. Serious adverse events were also similar, with one in the tacrolimus group and none in the beclometasone group. Total adverse events showed little difference as well, with 21 of 44 on tacrolimus and 14 of 44 on beclometasone experiencing them. The certainty of these results is low due to high imprecision.
What’s next
further research is needed to determine the optimal use of tacrolimus in treating ulcerative colitis and to compare its efficacy and safety with other available treatments.